{
    "2020-07-15": [
        [
            {
                "time": "",
                "original_text": "高瓴资本频现定增战投名单，医药生物股成其偏爱领域",
                "features": {
                    "keywords": [
                        "高瓴资本",
                        "定增",
                        "战投",
                        "医药生物"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "7年巨亏130亿，这家公司又获得超20亿美元投资 重大损失",
                "features": {
                    "keywords": [
                        "巨亏",
                        "投资",
                        "重大损失"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}